Last updated: June 12, 2026
Who supplies calcipotriene and betamethasone dipropionate APIs for fixed-dose combination products?
Short answer: API supply is split between (1) calcipotriene API suppliers and (2) betamethasone dipropionate API suppliers, with many downstream drug-product makers relying on contract API manufactures and custom blending/filling partners. The combination strength in marketed products is typically 0.005% calcipotriene + 0.064% betamethasone dipropionate (and equivalent strengths for foam, ointment, and other topical dosage forms).
Calcipotriene API: common sourcing categories
- API-only manufacturers supplying calcipotriene to finished-dose marketers via DMF/ASMF relationships.
- Integrated topical formulators that either produce API in-house or secure it from a preferred API vendor and control lot release through their quality agreements.
- Contract manufacturing organizations (CMOs) that source calcipotriene API for the formulators but do not directly market the API.
Betamethasone dipropionate API: common sourcing categories
- Steroid API specialists supplying betamethasone dipropionate to topical combination producers.
- Global API platforms with polymorph and impurity control programs that support stability and regulatory comparability for ANDA launches.
What buyers typically screen in supplier due diligence
- DMF/ASMF status (approved references for intended geography, dosage form, and specification).
- Impurity profile consistency (steroid impurities, residual solvents, related substances).
- Particle size and form control (calcipotriene form and dispersion behavior in semi-solids).
- Scale-up experience for topical creams, ointments, and foams (propylene glycol/ethanol systems for foam).
- Regulatory audit history for sterile? (typically not sterile for topical) and for non-sterile facilities.
Which companies manufacture calcipotriene-betamethasone dipropionate topical drug product (cream/ointment/gel/foam)?
Short answer: Multiple generic and branded drug-product manufacturers supply the fixed-dose combination across jurisdictions. The key commercial question is whether a supplier owns the product manufacturing site, or manufactures via a contract route.
Finished-dose supply routes that matter commercially
- Brand manufacturer supply
- Owns or contracts formulation, filling, and packaging under brand specifications.
- Generic drug-product manufacturer supply (ANDA route in the US)
- Sources APIs and manufactures the finished product at an approved site, typically with a published quality system and packaging controls.
- Licensing and co-marketing
- A drug-product marketer can license the formulation but still relies on a separate manufacturing site and batch release chain.
DOSAGE form segmentation (affects supplier ecosystem)
- Ointment/cream: higher dependence on semi-solid blending, homogenization, and packaging compatibility.
- Foam: higher dependence on aerosol/pressurized dispensing system design, propellant compatibility, and moisture control.
- Gel/solution variants: greater sensitivity to solvent system behavior and viscosity control.
What does the supplier map look like by geography (US, EU, UK, and select ROW markets)?
Short answer:
- US: finished-dose supply is dominated by ANDA and branded topicals sold through major wholesalers, with API sourcing often from international DMF holders or ASMF-referenced API sites.
- EU/UK: supply is shaped by EMA/National variations in marketing authorization, with QP release and local batch release rules driving quality documentation and audit focus.
- ROW: often higher reliance on regional generics and distributors, with more variable manufacturing controls unless tied to proven brand-level quality systems.
Why geography changes supplier choices
- Regulatory requirements for topical equivalence (rheology, droplet/foam properties where applicable).
- Label and strength unit differences (w/w versus w/v presentations).
- Local pharmacovigilance obligations that require documented manufacturer traceability.
What patents and regulatory file links control who can supply the combination in the US market?
Short answer: Market entry timing is constrained by combination product exclusivities, formulation/device-related patents (especially for foam delivery), and method-of-use and composition patents. Supplier selection in practice is tied to:
- whether an entrant has a regulatory pathway approved,
- whether their product is protected by Orange Book-listed patents tied to the listed drug,
- and whether they can clear litigation and non-infringement/invalidity positions.
Regulatory pathway effect on supplier selection
- If the manufacturer is preparing an ANDA, the API supplier must support comparability for the referenced strength and dosage form, including impurities and particle characteristics.
- If the dosage form is reformulated (e.g., foam versus ointment), supplier requirements shift toward the foam system and its excipient compatibility.
How do contract manufacturers typically support calcipotriene-betamethasone dipropionate supply?
Short answer: CMOs supply one or more of: blending and compounding, filling into tubes/containers, foam canister packaging, and stability program execution.
Most common CMO capabilities needed
- Semi-solid compounding lines with controlled mixing cycles and validated homogenization.
- Packaging line capability to avoid separation, leakage, or label/process incompatibility.
- Foam filling capability for pressurized canisters (if foam form is targeted).
- Stability testing (ICH and accelerated) tailored to topical product chemistry.
Supplier risk points
- Batch-to-batch variability in dispersion (calcipotriene content uniformity).
- Container compatibility (adsorption, permeation, actuator interactions for foam).
- Propellant system consistency for foam.
What commercial supplier options exist for downstream brands and generics?
Short answer: Buyers generally choose between three procurement models:
- Vertical procurement (API and finished dose sourced from a single group or closely aligned partners)
- Best-quality procurement (pick top API vendor and separate best-in-class CMO for the dosage form)
- Regulatory-file-driven procurement (use the API referenced in an approved DMF and align CMO release testing to match the filing strategy)
How procurement model affects lead time
- File-driven procurement is faster for release comparability but can constrain vendor competition.
- Best-quality procurement can increase lead time due to method harmonization and qualification.
What supplier-led quality standards are most important for this topical steroid/ vitamin D analog combination?
Short answer: Audit readiness, impurity control, and stability are the gating items.
Key quality systems to verify in supplier audits
- Master batch record controls for compounding and filling.
- Verified content uniformity and assay for both actives.
- Related substances control for betamethasone dipropionate and calcipotriene.
- Container closure integrity testing for foam and tube integrity for creams/ointments.
- Controlled change management (post-approval changes to excipients, mixing parameters, or packaging).
Key Takeaways
- Supply of calcipotriene + betamethasone dipropionate relies on distinct upstream API vendors and downstream finished-dose manufacturers, with CMOs used for blending, filling, and foam canister packaging.
- Supplier due diligence focuses on DMF/ASMF alignment, impurity profiles, dispersion/content uniformity, and container compatibility.
- Commercial entry and vendor qualification are closely tied to regulatory pathway strategy and Orange Book patent status for the specific marketed strength and dosage form.
FAQs
- Are there different supplier requirements for calcipotriene-betamethasone foam versus cream or ointment?
- Do API DMFs for calcipotriene and betamethasone dipropionate need to match the exact dosage form composition for regulatory submissions?
- What quality tests most often drive supply rejection for topical steroid analog combinations?
- How do packaging and container compatibility issues affect supply continuity for betamethasone dipropionate formulations?
- What documentation should a manufacturer demand from an API supplier for stability and impurity control in topical products?
References (APA)
- FDA. (n.d.). Drugs@FDA. U.S. Food and Drug Administration.
- EMA. (n.d.). European Medicines Agency: medicines database. European Medicines Agency.
Note: No specific supplier company list can be provided here without a validated mapping to named API/finished-dose manufacturers and the exact jurisdiction/dosage-form variants, which must be cited from primary sources (FDA Orange Book/Drugs@FDA, EMA/national product registers, and DMF/ASMF-linked filings).
